PT  - JOURNAL ARTICLE
AU  - TOSHIO INUI
AU  - DAISUKE KUCHIIKE
AU  - KENTARO KUBO
AU  - MARTIN METTE
AU  - YOSHIHIRO UTO
AU  - HITOSHI HORI
AU  - NORIHIRO SAKAMOTO
TI  - Clinical Experience of Integrative Cancer Immunotherapy with GcMAF
DP  - 2013 Jul 01
TA  - Anticancer Research
PG  - 2917--2919
VI  - 33
IP  - 7
4099  - http://ar.iiarjournals.org/content/33/7/2917.short
4100  - http://ar.iiarjournals.org/content/33/7/2917.full
SO  - Anticancer Res2013 Jul 01; 33
AB  - Background: Immunotherapy has become an attractive new strategy in the treatment of cancer. The laboratory and clinical study of cancer immunotherapy is rapidly advancing. However, in the clinical setting, the results of cancer immunotherapy are mixed. We therefore contend that cancer immunotherapy should be customized to each patient individually based on their immune status and propose an integrative immunotherapy approach with second-generation group-specific component macrophage activating factor (GcMAF)-containing human serum. Patients and Methods: The standard protocol of our integrative cancer immunotherapy is as follows: i) 0.5 ml GcMAF-containing human serum is administered intramuscularly or subcutaneously once or twice per week for the duration of cancer therapy until all cancer cells are eradicated; ii) hyper T/natural killer (NK) cell therapy is given once per week for six weeks; iii) high-dose vitamin C is administered intravenously twice per week; iv) alpha lipoic acid (600 mg) is administered orally daily; v) vitamin D3 (5,000-10,000 IU) is administered orally daily. Results: By March 2013, Saisei Mirai have treated over 345 patients with GcMAF. Among them we here present the cases of three patients for whom our integrative immunotherapy was remarkably effective. Conclusion: The results of our integrative immunotherapy seem hopeful. We also plan to conduct a comparative clinical study.>